Newron Pharmaceuticals S.p.A.

NWRN

IT0004147952

Biotechnology & Medical Research

Delayed Swiss Exchange Other stock markets 06:04:03 2025-01-24 am EST			5-day change	1st Jan Change
9.380 ^CHF	+0.32%		+5.51%	+4.80%

Jan. 09	Newron Pharmaceuticals S.p.A. and Myung In Pharm Co. Ltd. Announce License Agreement for Evenamide in South Korea	CI
Jan. 09	Newron Pharmaceuticals Enters Schizophrenia Drug License Deal in South Korea	MT

Newron Pharmaceuticals' H1 Net Loss Widens; Revenue Down

September 19, 2024 at 02:10 am EDT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A. and Myung In Pharm Co. Ltd. Announce License Agreement for Evenamide in South Korea	Jan. 09	CI
Newron Pharmaceuticals Enters Schizophrenia Drug License Deal in South Korea	Jan. 09	MT
Newron Pharmaceuticals S.p.A. Announce License Agreement with EA Pharma Co., Ltd	Dec. 13	CI
Newron Pharmaceuticals Signs Schizophrenia Drug License Deal in Japan, Asia	Dec. 13	MT
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2024	24-09-19	CI
Newron Pharmaceuticals' H1 Net Loss Widens; Revenue Down	24-09-19	MT
Newron Pharmaceuticals S.p.A. - Analyst/Investor Day	24-06-25
Newron Pharmaceuticals S.P.A Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients	24-05-13	CI
Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	24-04-30	CI
Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member	24-04-16	CI
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	24-03-19	CI
Newron Pharmaceuticals S.p.A., 2023 Earnings Call, Mar 19, 2024	24-03-19
Newron Pharmaceuticals' FY23 Loss Narrows; Revenue Up	24-03-19	MT
Newron Pharmaceuticals S.p.A. Auditor Raises 'Going Concern' Doubt	24-03-18	CI
Newron Pharmaceuticals S.p.A. Announces Agreement with the European Investment Bank to Extend the Near-Term Tranche Repayment Dates of Its 2018 Financing Agreement	24-03-15	CI
Newron Pharmaceuticals Secures Extension on Three Loan Repayments	24-03-15	MT
Newron Pharmaceuticals Investor Subscribes for Nearly EUR6 Million Shares	24-03-15	MT
Swiss Equities Edge Higher as Markets Continue to Weigh Rate Cut Outlook	24-01-04	MT
Newron Pharmaceuticals S.p.A. - Special Call	24-01-04
Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia	24-01-04	CI
Newron Pharmaceuticals' Schizophrenia Drug Lowers Disease Severity in Clinical Studies	24-01-04	MT
Swiss Equities Rally as Economic Barometer Hits Eight-month High at Year-end	23-12-29	MT
Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide	23-12-29	CI
Newron Pharmaceuticals Completes Enrolment of Schizophrenia Patients for Evenamide Clinical Study	23-12-29	MT
Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia	23-10-09	CI

Chart Newron Pharmaceuticals S.p.A.

Duration

Period

NWRN: Dynamic Chart

Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinsonâs disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-03-17 - Q4 2024 Earnings Release (Projected)

More about the company